# Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A Biotech Play with 71.52% Potential Upside

- Link: https://www.directorstalkinterviews.com/zevra-therapeutics-inc-zvra-stock-analysis-a-biotech-play-with-71-52-potential-upside/4121208112
- Published: 2025-07-18T10:36:46+01:00
- Author: Madison Wilson

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) has emerged as a noteworthy player within
the biotech sector, particularly for investors looking to capitalize on the potential
of rare disease treatments. With a market capitalization of $692.24 million, this
U.S.-based company is making strides in the healthcare industry, focusing on addressing
unmet needs through its innovative Ligand Activated Technology platform.

The current stock price stands at $12.66, showing a modest increase of 0.03% recently.
The 52-week range highlights a low of $5.50 and a high of $12.79, underscoring significant
volatility and the potential for robust returns. Investors may find its forward-
looking metrics appealing, particularly the forward P/E ratio of 19.65, even as 
some valuation metrics remain unavailable.

One of the standout figures for Zevra Therapeutics is its impressive revenue growth,
recorded at an astounding 495.70%. However, the company is yet to achieve profitability,
as evidenced by an EPS of -1.94 and a concerning Return on Equity of -204.78%. The
negative free cash flow of $39.2 million further highlights the financial challenges
faced as the company invests heavily in its pipeline.

Zevra Therapeutics focuses on groundbreaking treatments for rare diseases, with 
products such as KP1077, currently in clinical trials for idiopathic hypersomnia
and narcolepsy, and Celiprolol, undergoing Phase 3 trials for vascular Ehlers Danlos
syndrome. Additionally, the company offers AZSTARYS for ADHD, OLPRUVA for urea cycle
disorders, and MIPLYFFA for Niemann-Pick disease type C, reflecting a diverse and
promising product portfolio.

Analyst sentiment towards Zevra Therapeutics appears overwhelmingly positive, with
seven buy ratings and no hold or sell recommendations. The average target price 
of $21.71 suggests a potential upside of 71.52%, making it an attractive proposition
for growth-oriented investors. The target price range between $15.00 and $25.00 
further emphasizes the optimistic outlook on the stock’s potential.

From a technical analysis perspective, the stock is trading above both its 50-day
and 200-day moving averages, which are $9.36 and $8.39, respectively. This bullish
trend is supported by a Relative Strength Index (RSI) of 58.97, indicating the stock
is neither overbought nor oversold. The MACD of 1.03, above the signal line of 0.79,
further suggests bullish momentum.

Zevra Therapeutics, originally known as KemPharm, Inc., rebranded in February 2023
to better reflect its mission and focus. Headquartered in Celebration, Florida, 
the company has established strategic partnerships, such as with Commave Therapeutics
SA and Acer and Relief Therapeutics, Inc., to advance its product candidates and
expand commercial rights.

For investors with a high-risk appetite and a keen interest in biotechnology, Zevra
Therapeutics offers a compelling investment opportunity, albeit with the inherent
risks associated with clinical-stage biotech firms. Its focus on rare diseases, 
combined with a robust pipeline and potential for significant upside, positions 
Zevra Therapeutics as a stock worth watching in the healthcare sector.

Share on: